Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.13.5191

Arsenic Trioxide Promotes Paclitaxel Cytotoxicity in Resistant Breast Cancer Cells  

Bakhshaiesh, Tayebeh Oghabi (Drug Applied Research Centre)
Armat, Marzie (Drug Applied Research Centre)
Shanehbandi, Dariush (Immunology Research Center)
Sharifi, Simin (Department of Pharmaceutical Biotechnology, Faculty of Pharmacy)
Baradaran, Behzad (Immunology Research Center)
Hejazi, Mohammad Saeed (Drug Applied Research Centre)
Samadi, Nasser (Drug Applied Research Centre)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.13, 2015 , pp. 5191-5197 More about this Journal
Abstract
A partial response or resistance to chemotherapeutic agents is considered as a main obstacle in treatment of patients with cancer, including breast cancer. Refining taxane-based treatment procedures using adjuvant or combination treatment is a novel strategy to increase the efficiency of chemotherapy. PPM1D is a molecule activated by reactive oxygen species. whose expression is reported to modulate the recruitment of DNA repair molecules. In this study we examined the impact of arsenic trioxide on efficacy of paclitaxel-induced apoptosis in paclitaxel-resistant MCF-7 cells. We also investigated the expression of PPM1D and TP53 genes in response to this combination treatment. Resistant cells were developed from the parent MCF-7 cell line by applying increasing concentrations of paclitaxel. MTT assays were applied to determine the rate of cell survival. DAPI staining using fluorescent microscopy was employed to study apoptotic bodies. Real-time RT-PCR analysis was also applied to determine PPM1D mRNA levels. Our results revealed that combination of arsenic trioxide and paclitaxel elevates the efficacy of the latter in induction of apoptosis in MCF-7/PAC resistant cells. Applying arsenic trioxide also caused significant decreases in PPM1D mRNA levels (p<0.05). Our findings suggest that arsenic trioxide increases paclitaxel-induced apoptosis by down regulation of PPM1D expression. PPM1D dependent signaling can be considered as a novel target to improve the efficacy of chemotherapeutic agents in resistant breast cancer cells.
Keywords
Combination therapy; arsenic trioxide; resistant breast cancer; taxanes; Wip1;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Ali AY, Farrand L, Kim JY, et al (2012). Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum. Ann NY Acad Sci, 1271, 58-67.   DOI
2 Baj G, Arnulfo A, Deaglio S, et al (2002). Arsenic trioxide and breast cancer: analysis of the apoptotic, differentiative and immunomodulatory effects. Breast Cancer Res Treat, 73, 61-73.   DOI
3 Bauer JA, Ye F, Marshall CB, et al (2010). RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. Breast Cancer Res, 12, 41.
4 Branham MT, Nadin SB, Vargas-Roig LM, et al (2004). DNA damage induced by paclitaxel and DNA repair capability of peripheral blood lymphocytes as evaluated by the alkaline comet assay. Mutat Res, 560, 11-7.   DOI
5 Bulavin DV, Demidov ON, Saito S, et al (2002). Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet, 31, 210-5.   DOI
6 Burns TF, Fei P, Scata KA, et al (2003). Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells. Molec Cell Biol, 23, 5556-71.   DOI
7 Cai X, Yu Y, Huang Y, et al (2003). Arsenic trioxide-induced mitotic arrest and apoptosis in acute promyelocytic leukemia cells. Leukemia, 17, 1333-7.   DOI
8 Cheng B, Yang X, Han Z, et al (2008). Arsenic trioxide induced the apoptosis of laryngeal cancer via down-regulation of survivin mRNA. Auris Nasus Larynx, 35, 95-101.   DOI
9 Chou TC, Talalay P (1984). Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul, 22, 27-55.   DOI
10 Dogra S, Bandi S, Viswanathan P, et al (2015). Arsenic trioxide amplifies cisplatin toxicity in human tubular cells transformed by HPV-16 E6/E7 for further therapeutic directions in renal cell carcinoma. Cancer Lett, 356, 953-61.   DOI
11 Duan XF, Wu YL, Xu HZ, et al (2010). Synergistic mitosisarresting effects of arsenic trioxide and paclitaxel on human malignant lymphocytes. Chem Biol Interact, 183, 222-30.   DOI
12 Emadi A, Gore SD (2010). Arsenic trioxide-An old drug rediscovered. Blood Rev, 24, 191-9.   DOI
13 Fiscella M, Zhang H, Fan S, et al (1997). Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci U S A, 94, 6048-53.   DOI
14 Ghanbari P, Mohseni M, Tabasinezhad M, et al (2014). Inhibition of survivin restores the sensitivity of breast cancer cells to docetaxel and vinblastine. Appl Biochem Biotechnol.
15 Goncalves A, Braguer D, Kamath K, et al (2001). Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics. Proc Natl Acad Sci U S A, 98, 11737-42.   DOI
16 Ikui AE, Yang CP, Matsumoto T, et al (2005). Low concentrations of taxol cause mitotic delay followed by premature dissociation of p55CDC from Mad2 and BubR1 and abrogation of the spindle checkpoint, leading to aneuploidy. Cell Cycle, 4, 1385-8.   DOI
17 Gottesman MM (2002). Mechanisms of cancer drug resistance. Annu Rev Med, 53, 615-27.   DOI
18 Halicka HD, Smolewski P, Darzynkiewicz Z, et al (2002). Arsenic trioxide arrests cells early in mitosis leading to apoptosis. Cell Cycle, 1, 201-9.
19 Herbst RS, Khuri FR (2003). Mode of action of docetaxel-a basis for combination with novel anticancer agents. Cancer Treatment Reviews, 29, 407-15.   DOI
20 Kavallaris M (1997). The role of multidrug resistance-associated protein (MRP) expression in multidrug resistance. Anticancer Drugs, 8, 17-25.   DOI
21 Kong W, Jiang X, Mercer WE (2009). Downregulation of Wip-1 phosphatase expression in MCF-7 breast cancer cells enhances doxorubicin-induced apoptosis through p53-mediated transcriptional activation of Bax. Cancer Biol Ther, 8, 555-63.   DOI
22 Li Y, Qu X, Qu J, et al (2009). Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation. Cancer Letters, 284, 208-15.   DOI
23 Ling YH, Jiang JD, Holland JF, et al (2002). Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. Mol Pharmacol, 62, 529-38.   DOI
24 Liu H, Tao X, Ma F, et al (2012a). Radiosensitizing effects of arsenic trioxide on MCF-7 human breast cancer cells exposed to 89 strontium chloride. Oncol Rep, 28, 1894-902.
25 Lu X, Nguyen TA, Moon SH, et al (2008). The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastasis Rev, 27, 123-35.   DOI
26 Liu W, Gong Y, Li H, et al (2012b). Arsenic trioxide-induced growth arrest of breast cancer MCF-7 cells involving FOXO3a and IkappaB kinase beta expression and localization. Cancer Biother Radiopharm, 27, 504-12.   DOI
27 Lu X, Ma O, Nguyen TA, et al (2007). The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell, 12, 342-54.   DOI
28 Lu X, Nannenga B, Donehower LA (2005). PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev, 19, 1162-74.   DOI
29 McGrogan BT, Gilmartin B, Carney DN, et al (2008). Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta, 1785, 96-132.
30 Melet A, Song K, Bucur O, et al (2008). Apoptotic pathways in tumor progression and therapy. Adv Exp Med Biol, 615, 47-79.   DOI
31 Meng XZ, Zheng TS, Chen X, et al (2011). microRNA expression alteration after arsenic trioxide treatment in HepG-2 cells. J Gastroenterol Hepatol, 26, 186-93.   DOI
32 Momand J, Jung D, Wilczynski S, et al (1998). The MDM2 gene amplification database. Nucleic Acids Res, 26, 3453-9.   DOI
33 Parssinen J, Alarmo EL, Karhu R, et al (2008). PPM1D silencing by RNA interference inhibits proliferation and induces apoptosis in breast cancer cell lines with wild-type p53. Cancer Genet Cytogenet, 182, 33-9.   DOI
34 Rossi M, Demidov ON, Anderson CW, et al (2008). Induction of PPM1D following DNA-damaging treatments through a conserved p53 response element coincides with a shift in the use of transcription initiation sites. Nucleic Acids Res, 36, 7168-80.   DOI
35 Parssinen J, Kuukasjarvi T, Karhu R, et al (2007). High-level amplification at 17q23 leads to coordinated overexpression of multiple adjacent genes in breast cancer. Br J Cancer, 96, 1258-64.   DOI
36 Platanias LC (2009). Biological responses to arsenic compounds. J Biol Chem, 284, 18583-7.   DOI
37 Rivas MA, Venturutti L, Huang YW, et al (2012). Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development. Breast Cancer Res, 14, 77.   DOI
38 Sabzichi M, Hamishehkar H, Ramezani F, et al (2014). Luteolinloaded phytosomes sensitize human breast carcinoma MDAMB 231 cells to doxorubicin by suppressing Nrf2 mediated signalling. Asian Pac J Cancer Prev, 15, 5311-6.   DOI
39 Samadi N, Bekele R, Capatos D, et al (2011). Regulation of lysophosphatidate signaling by autotaxin and lipid phosphate phosphatases with respect to tumor progression, angiogenesis, metastasis and chemo-resistance. Biochimie, 93, 61-70.   DOI
40 Samadi N, Gaetano C, Goping IS, et al (2009). Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis. Oncogene, 28, 1028-39.   DOI   ScienceOn
41 Samadi N, Ghanbari P, Mohseni M, et al (2014). Combination therapy increases the efficacy of docetaxel, vinblastine and tamoxifen in cancer cells. J Cancer Res Ther, 10, 715-21.
42 Takekawa M, Adachi M, Nakahata A, et al (2000). p53-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. Embo J, 19, 6517-26.   DOI
43 Sharifi S, Barar J, Hejazi MS, et al (2014). Roles of the Bcl-2/Bax Ratio, Caspase-8 and 9 in Resistance of Breast Cancer Cells to Paclitaxel. Asian Pac J Cancer Prev, 15, 8617-22.   DOI
44 Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30.   DOI   ScienceOn
45 Skidan I, Miao B, Thekkedath RV, et al (2009). In vitro cytotoxicity of novel pro-apoptotic agent DM-PIT-1 in PEGPE-based micelles alone and in combination with TRAIL. Drug Deliv, 16, 45-51.   DOI
46 Vousden KH, Lu X (2002). Live or let die: the cell's response to p53. Nat Rev Cancer, 2, 594-604.   DOI
47 Wahl GM, Carr AM (2001). The evolution of diverse biological responses to DNA damage: insights from yeast and p53. Nat Cell Biol, 3, 277-86.   DOI   ScienceOn
48 Wang L, Mosel AJ, Oakley GG, et al (2012). Deficient DNA damage signaling leads to chemoresistance to cisplatin in oral cancer. Mol Cancer Ther, 11, 2401-9.   DOI
49 Yoda A, Toyoshima K, Watanabe Y, et al (2008). Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1 phosphatase. J Biol Chem, 283, 18969-79.   DOI
50 Zekri A, Ghaffari SH, Yousefi M, et al (2013). Autocrine human growth hormone increases sensitivity of mammary carcinoma cell to arsenic trioxide-induced apoptosis. Mol Cell Endocrinol, 377, 84-92.   DOI